ISPE Will Discuss Breakthrough Therapies at 2013 ISPE Annual Meeting - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ISPE Will Discuss Breakthrough Therapies at 2013 ISPE Annual Meeting

Untitled Document

Pharmaceutical industry experts and global regulators will meet to discuss the FDA’s recent draft guidance on breakthrough therapies at the 2013 ISPE Annual Meeting, held on Nov. 3-6 in Washington, DC. The session, entitled “Breakthrough Therapy: Are You Ready for Approval?” will take place during the Global Regulatory and Compliance discussion sessions on Tuesday, Nov. 5.

The session will be led by Eric Thostesen, senior director, business support, Janssen Pharmaceutical and will feature talks from FDA’s Tara Gooen, Steve Kozlowski, and Sarah Pope Miksinski, as well as Earl Dye of Genetech, John Groskoph of Pfizer, and Patricia Hurter of Vertex Pharmaceuticals. Presentations will cover the FDA’s recent draft guidelines on breakthrough therapies and industry considerations related to the development process challenges associated with reduced filing time and global regulatory submissions. The goal of the session will be to align industry and FDA expectations on the breakthrough therapy designation and discuss next steps for moving forward with the draft guidelines.

Source: ISPE


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here